Abstract 3852
Background
Circulating tumor DNA (ctDNA) from liquid biopsy is a source of tumor genetic material for EGFR testing in NSCLC when resistance to I-II generations TKI-therapies occurs or upfront, in absence of tissue biopsy. A multi-regional survey for patients treated with EGFR TKI from January to December 2018 was conducted regarding use of liquid biopsy for NSCLC in clinical practice.
Methods
Aim of the study was to describe EGFR testing workflow by liquid biopsy in clinical setting. Seven major lung-cancer centers in North Eastern Italy participated to the survey.
Results
Overall 316 patients (360 samples) have been screened for ctDNA EGFR, with a medium number of 1.1 samples/patient. All institutions reported EGFR as the main gene tested for clinical purposes in plasma samples of NSCLC, other genes (i.e. KRAS/BRAF) were occasionally tested upon oncologist request. Seven out of seven (100%) centers used commercially available real time CE-IVD tests. NGS or droplet digital PCR were used by one center each, as confirmation methods. In all institutions blood drawing was performed in the same hospital of EGFR testing (in 6/7 - 86%- centers in the Medical Oncology Unit), and plasma separated within 2 hours. EGFR testing was performed in the Surgical Pathology Unit and report edited within 24 hours in 3/7 (43%) centers and within 3-5 working days in 4/7 (57%) centers. Among all, 108 (34%) patients were tested at the time of diagnosis with an EGFR mutation rate of 15%. At progression to TKI treatment, 208 (66%) patients were tested. T790M positive rate was 55/122 (45%). Inconclusive cases (negative for both T790M and known actionable mutation) were 86 (41%). All centers declared that histo/cytological re-biopsy was suggested in these cases.
Conclusions
Real-world experiences about EGFR testing in liquid biopsies revealed homogeneous habits among interviewed centers, according to national guidelines and literatures data. The consistent number of liquid biopsies at the time of diagnosis mainly refers to some reference centers that collect specimens from several institutions. However it might impose a revision of bronchoscopy workflows in order to obtain better samples suitable both for cito-histological diagnosis and molecular profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract